StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Segment Expense Disaggregation (Note 2) by Year

Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M) ($M)

Amgen Segment Expense Disaggregation (Note 2): $9,845M in FY2025, down 11.4% from a year earlier.

Latest, FY2025
9,845
Period ended Dec 31, 2025
Change on a year earlier
-11.4%
11,118 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Note 2 Segment Reporting (ASC 280-10-50-26A).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSegment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M) ($M)Year on yearSource
FY2025Dec 31, 20259,845-11.4%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202411,118+51.3%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 20237,347+27.2%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 20225,776–Form 10-K (filed 2025-02-14) ↗

Breakdown

What makes up segment Expense Disaggregation (Note 2)

Cite this data

StockData. (2026). Amgen Segment Expense Disaggregation (Note 2) ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/seg-mfg-cogs

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.